Global Parkinson’s Disease Treatment Market, By Drug Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Other Drugs), Medical Devices (Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices), Route of Administration (Oral, Transdermal, Subcutaneous, Intestinal Infusion, Others), Distribution Channel (Hospital Pharmacies, Clinics, Retail Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics) – Industry Trends and Forecast to 2030.
Parkinson’s Diseases Treatment Market Analysis and Size
Parkinson's disease is a relatively common neurological disorder, with an estimated incidence of 10 per 100,000 people per year. The incidence of Parkinson's disease increases with age, with the majority of cases occurring in people over the age of 60. The prevalence of Parkinson's disease also varies by region, with higher rates reported in North America and Europe compared to other parts of the world. It is estimated that approximately 1% of the population over the age of 60 is affected by Parkinson's disease, with the prevalence increasing to 4-5% in people over the age of 85. It is worth noting that the incidence and prevalence of Parkinson's disease may be underestimated due to the difficulty in diagnosing the disease in its early stages, as well as the lack of standardized diagnostic criteria.
Data Bridge Market Research analyses that the Parkinson’s disease treatment market which was USD 4,999.18 million in 2022, would rocket up to USD 10,034.52 million by 2030, and is expected to undergo a CAGR of 9.10% during the forecast period. This indicates the market value. “Levodopa/Carbidopa” dominates the drug class segment of the Parkinson’s disease treatment market owing to the growing demand for better treatment of neurological disorders. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Parkinson’s Diseases Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
Drug Class (Levodopa/Carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-Inhibitors, Anticholinergics, Other Drugs), Medical Devices (Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices), Route of Administration (Oral, Transdermal, Subcutaneous, Intestinal Infusion, Others), Distribution Channel (Hospital Pharmacies, Clinics, Retail Pharmacies, Online Pharmacies), Patient Care Setting (Hospitals, Clinics)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
GlaxoSmithKline plc. (U.K), Teva Pharmaceutical Industries Ltd. (Isarel), Boehringer Ingelheim International GmbH. (Germany), Impax Laboratories LLC (U.S), AbbVie Inc. (U.S), Bausch Health. (Canada), Lundbeck (Denmark), Sun Pharmaceutical Industries Ltd. (India), ACADIA Pharmaceuticals Inc. (U.S), Merck & Co. Inc. (U.S), Novartis AG (Switzerland), UCB S.A. (Belgium), Dr. Reddy’s Laboratories Ltd. (India), WOCKHARDT. (India), F. Hoffmann-La Roche Ltd (Switzerland), STADA Arzneimittel AG (Germany), Orion Corporation. (Finland), Mylan N.V. (U.K), Cipla Inc. (India), Par Pharmaceutical. (U.S), DAIICHI SANKYO COMPANY LIMITED. (Japan), and Apotex Inc (Canada)
|
|
Market Opportunities
|
|
Market Definition
Parkinson’s disease is the combination of progressive, degenerative neurological motor disorder, mainly affecting the dopaminergic cells of the brain. Tremor, rigidity, bradykinesia and postural volatility are some of the common symptoms of Parkinson’s disease.
Global Parkinson’s Diseases Treatment Market Dynamics
Drivers
- Advancements in Drug Development
There have been significant advancements in drug development for Parkinson's disease in recent years, including the development of new therapies that target specific pathways in the disease process. This has led to the introduction of new drugs and treatment options, driving growth in the market.
- Increasing Healthcare Expenditure
The growing healthcare expenditure in both developed and developing countries is expected to drive the growth of the Parkinson's disease treatment market. With increasing access to healthcare and rising awareness about Parkinson's disease, more patients are seeking treatment, driving demand for drugs and therapies.
Opportunities
- Government Initiatives and Funding
Governments around the world are investing in research and development to find new treatments for Parkinson's disease. This funding is driving innovation and helping to bring new treatments to market, further driving growth in the market.
- Improved Diagnostic Tools
The development of improved diagnostic tools for Parkinson's disease presents an opportunity to identify patients at earlier stages of the disease and provide more effective treatment. This could lead to better outcomes and reduce the overall burden of the disease on patients and healthcare systems.
Restraints/Challenges
- High Cost of Treatment
The high cost of treatment and limited awareness and understanding of the disease are the factors that will hinder the market growth and will further challenge Parkinson’s disease treatment. Also, the lack of disease-modifying therapies and limited efficacy of current treatments, the heavy customs duty imposed on medical devices and treatment accessories, and the lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.
This Parkinson’s disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Parkinson’s disease treatment market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In June 2021, Biogen announced that it had completed the acquisition of TMS-007, a Phase 2-ready asset for the treatment of Parkinson's disease. TMS-007 is a small molecule inhibitor of the leucine-rich repeat kinase 2 (LRRK2) protein, which is believed to play a role in the development of Parkinson's disease
- In May 2021, Roche announced positive Phase 3 trial results for its investigational drug, prasinezumab, for the treatment of Parkinson's disease. Prasinezumab is a monoclonal antibody that targets alpha-synuclein, a protein that is believed to contribute to the development of Parkinson's disease
- In April 2021, AbbVie announced positive Phase 2 trial results for its investigational drug, ABBV-951, for the treatment of Parkinson's disease. ABBV-951 is a levodopa-carbidopa intestinal gel (LCIG) that is delivered via a pump system and is designed to provide continuous delivery of medication to reduce motor fluctuations in Parkinson's disease patients
- In March 2021, Sunovion announced that it had received FDA approval for its drug, Kynmobi, for the treatment of Parkinson's disease. Kynmobi is a sublingual film formulation of apomorphine, a dopamine agonist that is used to treat "off" episodes in Parkinson's disease patients.
Global Parkinson’s Disease Treatment Market Scope
The Parkinson’s disease Treatment market is segmented on the basis of drug class, medical devices, route of administration, distribution channel and patient care setting. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Levodopa/Carbidopa
- Dopamine Receptor Agonists
- MAO-Inhibitors
- COMT-Inhibitors
- Anticholinergics
- Other Drugs
Medical Devices
- Deep Brain Stimulation (DBS) Devices
- Carbidopa/Levodopa Enteral Suspension (Duopa) Delivery Devices
Route of Administration
- Oral
- Transdermal
- Subcutaneous
- Intestinal Infusion
- Others
Distribution Channel
- Hospital Pharmacies
- Clinics
- Retail Pharmacies
- Online Pharmacies
Patient Care Setting
- Hospitals
- Clinics
Global Parkinson’s Disease Treatment Market Regional Analysis/Insights
The global Parkinson’s disease Treatment market is analyzed and market size insights and trends are provided by country, drug class, medical devices, route of administration, distribution channel, and patient care setting, as referenced above.
The countries covered in the Parkinson’s Disease Treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the Parkinson’s disease treatment market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having neurological diseases, especially Parkinson’s disease.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for neurological diseases, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Parkinson’s disease treatment market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the Parkinson’s disease Treatment market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the Parkinson’s disease treatment market.
Competitive Landscape and Parkinson’s Disease Market Share Analysis
The Parkinson’s disease Treatment market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the Parkinson’s disease Treatment market.
Some of the major players operating in the Parkinson’s disease treatment market are:
- GlaxoSmithKline plc. (U.K)
- Teva Pharmaceutical Industries Ltd. (Isarel)
- Boehringer Ingelheim International GmbH. (Germany)
- Impax Laboratories LLC (U.S)
- AbbVie Inc. (U.S)
- Bausch Health. (Canada)
- Lundbeck (Denmark)
- Sun Pharmaceutical Industries Ltd. (India)
- ACADIA Pharmaceuticals Inc. (U.S)
- Merck & Co. Inc. (U.S)
- Novartis AG (Switzerland)
- UCB S.A. (Belgium)
- Dr. Reddy’s Laboratories Ltd. (India)
- WOCKHARDT. (India)
- F. Hoffmann-La Roche Ltd (Switzerland)
- STADA Arzneimittel AG (Germany)
- Orion Corporation. (Finland)
- Mylan N.V. (U.K)
- Cipla Inc. (India)
- Par Pharmaceutical. (U.S)
- DAIICHI SANKYO COMPANY LIMITED. (Japan)
- Apotex Inc (Canada)
SKU-